Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Gastrointestinal 1

Conditions

Malignant Solid Tumor 1Hepatitis C 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 593Cyclophosphamide 539Magnetic Resonance Spectroscopy 527Radiotherapy 506Specimen Handling 504Nivolumab 406Cisplatin 370Carboplatin 360Biopsy 306Blood Specimen Collection 296Radiosurgery 284Paclitaxel 276Surveys and Questionnaires 269Standard of Care 267Gemcitabine 266fludarabine 261Dexamethasone 258Drug Therapy 256Bevacizumab 248venetoclax 247Oxaliplatin 206Rituximab 197Capecitabine 194Radiation 190Fluorouracil 186Ipilimumab 183durvalumab 181Doxorubicin 174atezolizumab 172Etoposide 171

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Ribavirin × 1 year × Clear all
NCT01309490 2025-07-29

Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients

Jewish General Hospital

Phase 1/2 Terminated
5 enrolled
Other solid neoplasm

Malignant Solid Tumor

NCT02940496 2025-07-15

Pembrolizumab (MK-3475) in Hepatocellular Carcinoma

M.D. Anderson Cancer Center

Phase 2 Completed
15 enrolled 8 charts
Gastrointestinal

Hepatitis C, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡